Drugs / ANVATABART OPADOTIN
ANVATABART OPADOTIN
also known as
ARX788 · Anvatabart opadotina · Anvatabart opadotine · Anvatabart opafidotin · ARX788 ADC
Other / unclassified targets ERBB2
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03255070 | Mar 2018 → Sep 2023 | breast cancer, gastric cancer | Ambrx, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02512237 | Mar 2016 → Jan 2017 | breast neoplasm, gastric neoplasm | Zhejiang Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT06224673 | Jun 2026 → Nov 2029 expected | hormone receptor-positive breast cancer, triple-negative breast carcinoma | Laura Huppert, MD, BA | Recruiting | No outcome recorded |
| Phase 2 | NCT06663748 | Nov 2024 → Nov 2025 overdue | HER2 positive breast carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06578286 | Sep 2024 → Sep 2026 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05041972 | Nov 2021 → Apr 2022 | — | Ambrx, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04829604 | Oct 2021 → Dec 2026 expected | HER2 positive breast carcinoma | Ambrx, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05018676 | Oct 2021 → Dec 2022 | breast carcinoma by gene expression profile | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04983121 | Aug 2021 → Aug 2027 expected | breast neoplasm | Shengjing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05018702 | Jul 2021 → Dec 2022 | HER2 positive breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05426486 | May 2022 → Dec 2025 overdue | HER2 positive breast carcinoma | Caigang Liu | Active not recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANVATABART OPADOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297892 ↗ |
| Known as | Anvatabart opadotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297892 ↗ |
| Known as | Anvatabart opadotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297892 ↗ |
| Known as | Anvatabart opafidotin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297892 ↗ |
| Known as | ARX788 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06224673 ↗ |
| Known as | ARX788 ADC | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297892 ↗ |
| Modality | Other / unclassified | “ARX788, an antibody drug conjugate” NCT02512237 ↗ |
| Route | Intravenous | “ARX788, 1.5 mg/kg Q3W, IV for 12 weeks” NCT01042379 ↗ |
| Target | ERBB2 | “human epidermal growth factor receptor 2 (HER2)-targeting” NCT04983121 ↗ |